FOXP3 and Leigh syndrome: Combination a-TEA-LS + ICB therapy had minimal impact on the frequency of effector Foxp3-CD4+ (Teff) or regulatory Foxp3+CD4+ (Treg) T cells, although we detected an increase in Tregs following aPD-1 as compared to the a-TEA-LS-treated group.